Bristol-Myers Squibb (BMY) Faces Mixed Analyst Sentiment Despite Strong Momentum in Healthcare Industry

What: Bristol-Myers Squibb (BMY) is experiencing mixed analyst sentiment despite strong momentum in the healthcare industry.
Why: Analysts are divided on the company's growth prospects due to its recent acquisitions and pipeline developments.
Signal: BMY's stock price has risen **15%** in the past quarter, indicating investor confidence in the company's potential.
Target: Analysts have set a median price target of **$85** for BMY, reflecting a potential upside of **10%** from its current price.
Risk: Regulatory challenges and competition in the pharmaceutical industry pose significant risks to BMY's future growth and profitability.